AP9200405A0 - Pharmaceutical formulations comprised of micronised halofantrine. - Google Patents

Pharmaceutical formulations comprised of micronised halofantrine.

Info

Publication number
AP9200405A0
AP9200405A0 APAP/P/1992/000405A AP9200405A AP9200405A0 AP 9200405 A0 AP9200405 A0 AP 9200405A0 AP 9200405 A AP9200405 A AP 9200405A AP 9200405 A0 AP9200405 A0 AP 9200405A0
Authority
AP
ARIPO
Prior art keywords
halofantrine
micronised
pharmaceutical formulations
formulations comprised
comprised
Prior art date
Application number
APAP/P/1992/000405A
Inventor
John Norman Charles Healey
Marshall Whiteman
Original Assignee
Smithkline Beecham Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB919115232A external-priority patent/GB9115232D0/en
Priority claimed from GB919115231A external-priority patent/GB9115231D0/en
Application filed by Smithkline Beecham Ag filed Critical Smithkline Beecham Ag
Publication of AP9200405A0 publication Critical patent/AP9200405A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Novel formulations of the anti-malarial compoundhalofantrine and pharmaceutically acceptable salts thereof, having improved bioavailability.
APAP/P/1992/000405A 1991-07-15 1992-07-13 Pharmaceutical formulations comprised of micronised halofantrine. AP9200405A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB919115232A GB9115232D0 (en) 1991-07-15 1991-07-15 Compounds
GB919115231A GB9115231D0 (en) 1991-07-15 1991-07-15 Compound

Publications (1)

Publication Number Publication Date
AP9200405A0 true AP9200405A0 (en) 1994-01-13

Family

ID=26299235

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1992/000405A AP9200405A0 (en) 1991-07-15 1992-07-13 Pharmaceutical formulations comprised of micronised halofantrine.

Country Status (7)

Country Link
CN (1) CN1068494A (en)
AP (1) AP9200405A0 (en)
AU (1) AU2279292A (en)
IE (1) IE922289A1 (en)
MX (1) MX9204103A (en)
PT (1) PT100686A (en)
WO (1) WO1993001809A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9507437A (en) * 1994-04-07 1997-09-16 Smithkline Beecham Plc Halofantrine-free base and compositions for the treatment of malaria
GB0112497D0 (en) * 2001-05-22 2001-07-11 Smithkline Beecham Plc Formulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH19255A (en) * 1983-09-16 1986-02-17 Smithkline Beckman Corp Salts of antimalarial phenanthrene methanol compounds
AU633499B2 (en) * 1988-06-30 1993-02-04 Michael H. Davis Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo

Also Published As

Publication number Publication date
PT100686A (en) 1993-08-31
WO1993001809A1 (en) 1993-02-04
MX9204103A (en) 1993-02-01
CN1068494A (en) 1993-02-03
IE922289A1 (en) 1993-01-27
AU2279292A (en) 1993-02-23

Similar Documents

Publication Publication Date Title
FI942092A7 (en) Government-approved product
NZ244021A (en) Benzylthiazolidinedione derivatives, preparation and pharmaceutical compositions thereof
ES2179040T3 (en) USE OF 5-FLUORO-2'-DESOXI-3'-THIACITIDINE FOR THE TREATMENT OF HEPATITIS B.
FI951901L (en) Stable extended-release, orally administered formulation
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
SG46413A1 (en) Substituted 4-phenyl-4-piperdinecarboxamides with both local anaesthetic and analgesic effect as well as processes for their preparation
AU3354895A (en) Novel medicinal use of 5ht3 antagonist
HU9501623D0 (en) Use of 2-amino-6-a-propylamino-4,5,6,7-tetrahydrobenzothiazole (pramipexol) as an antidepressant drug
IL98310A0 (en) The pharmacological use of certain cystine derivatives
DK515489D0 (en) DISPERSIBLE PHARMACEUTICAL FORMULATION
CA2087543A1 (en) Heterocyclic compounds
TW221441B (en)
ES2062137T3 (en) USE OF 5'-DEOXI-5'-METHYL-THIOADENOSINE, S-ADENOSYLMETIONINE AND ITS SALTS FOR THE PREPARATION OF REDUCING PHARMACEUTICAL COMPOSITIONS OF SEBORRHEA.
GR3031542T3 (en) Cephalosporinderivatives and process for its preparation
IL105276A (en) (S)-a-PHENYL- 2-PYRIDINEETHANAMINE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT
TW366284B (en) Pharmaceutical antitussive composition of delta-receptor antagonist
AU1643592A (en) Novel compound and use of the same as medicine
AP9200405A0 (en) Pharmaceutical formulations comprised of micronised halofantrine.
IL76345A0 (en) Proline derivatives and antihypertensive and anti-glaucoma pharmaceutical preparations containing the same
BG106151A (en) Pharmaceutical complex
LTIP1735A (en) Use of bambuterol for the manufacture of a pharmaceutical preparation with lipid lowering effect
EP0523013A3 (en) Use of benzimidazoline-2-oxo-1-carboxylic acid derivatives in the treatment of organic mental diseases
EP0396169A3 (en) Pharmaceutical composition for topical ophthalmic use having improved local tolerability
AU1042888A (en) Pain-killer
EP0514687A3 (en) Process for the preparation of n,n-disubstituted m-aminophenols